Literature DB >> 12384194

The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison.

Rianne Oostenbrink1, Henriëtte A A Moll, Marie-Louise Essink-Bot.   

Abstract

Framed in a study on the cost-effectiveness of different diagnostic strategies regarding children with meningeal signs, this study evaluated the quality weights for permanent sequelae after childhood bacterial meningitis obtained with two different classification instruments: the EQ-5D, and Health Utilities Index (HUI). A panel of 28 pediatricians classified seven standardized descriptions of patients with permanent sequelae after bacterial meningitis according to the EQ-5D and HUI classification system. Quality weights for each classification were calculated using the EQ-5D and HUI standard scoring algorithms. HUI Mark 3 quality weights were substantially lower than the EQ-5D for all descriptions (mean difference 0.11; 95% CI: 0.08-0.14). Mean Kendall W for agreement of the ranking order between EQ-5D and HUI Mark 3 was 0.90. The EQ-5D and HUI resulted in different absolute quality weights, in particular for states associated with "deafness" and "mental retardation." Due to their performance differences, the HUI may be preferable to EQ-5D in studies focussed on "sensation" (hearing, vision, speech) or "cognition." These differences proved not to be relevant in the present cost-utility study of diagnostic strategies to rule out bacterial meningitis, as such consequences were at the distal end of the decision tree. This may be different in a cost-utility analysis of therapeutic strategies. Hence, sensitivity analysis to quality weights is recommended.

Entities:  

Mesh:

Year:  2002        PMID: 12384194     DOI: 10.1016/s0895-4356(02)00448-1

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  29 in total

Review 1.  The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.

Authors:  Robert Welte; Caroline L Trotter; W John Edmunds; Maarten J Postma; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Counselling of hearing aid users is highly cost-effective.

Authors:  Arja Vuorialho; Petri Karinen; Martti Sorri
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-06-24       Impact factor: 2.503

3.  Proxy assessment of quality of life in pediatric clinical trials: application of the Health Utilities Index 3.

Authors:  Cheryl L Cox; Shelly Lensing; Shesh N Rai; Pam Hinds; Elizabeth Burghen; Ching-Hon Pui
Journal:  Qual Life Res       Date:  2005-05       Impact factor: 4.147

4.  Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated?

Authors:  Wendy J Ungar
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

5.  Cost-effectiveness of the Haemophilus influenzae type b vaccine for infants in mainland China.

Authors:  Guijun Ning; Zundong Yin; Yixing Li; Huaqing Wang; Weizhong Yang
Journal:  Hum Vaccin Immunother       Date:  2017-11-27       Impact factor: 3.452

6.  A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.

Authors:  Pepijn Vemer; Maarten J Postma
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.

Authors:  Katelijne van de Vooren; Silvy Duranti; Alessandro Curto; Livio Garattini
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

8.  The predictive validity of health-related quality of life measures: mortality in a longitudinal population-based study.

Authors:  Mark S Kaplan; Jean-Marie Berthelot; David Feeny; Bentson H McFarland; Saeeda Khan; Heather Orpana
Journal:  Qual Life Res       Date:  2007-11       Impact factor: 4.147

9.  Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.

Authors:  Koen B Pouwels; Eelko Hak; Arie van der Ende; Hannah Christensen; Germie P J M van den Dobbelsteen; Maarten J Postma
Journal:  Hum Vaccin Immunother       Date:  2013-02-13       Impact factor: 3.452

10.  Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic.

Authors:  Jaime L Rubin; Lisa J McGarry; Keith P Klugman; David R Strutton; Kristen E Gilmore; Milton C Weinstein
Journal:  BMC Infect Dis       Date:  2010-01-21       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.